Madrigal reports ‘positive’ results from Phase 3 MAESTRO-NAFLD-1 trial
Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...
Madrigal Pharmaceuticals Phase 3 data ‘encouraging,’ says UBS
Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...
GlobalData on MSN4mon
Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug
MAESTRO-NASH OUTCOMES is a double-blind, randomised, placebo-controlled Phase III study involving ... and the MAESTRO-NAFLD-1 ...
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...